Chart Industries Divestiture of MVE Biological Products to Cryoport

Winston & Strawn represented Chart Industries, Inc. (NASDAQ: GTLS) in the divestiture of its cryobiological products business (MVE Biological Products) to Cryoport, Inc. (NASDAQ: CYRX) for US$320M in cash. The strategic decision to divest the cryobiological products business reflects Chart’s strategy and capital allocation approach to focus on its core capabilities and offerings while continuing to expand its presence in clean energy applications including LNG, hydrogen, biogas/biomethane, carbon capture and other renewable fueling sources.